Komori
Governance4886ASKA Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Notice Regarding the Transition to a Company with an Audit and Supervisory Committee

Subject to approval at the Annual General Meeting of Shareholders scheduled for 24 June 2026, the company decided to transition from a company with an audit and supervisory board and similar structures to a company with an audit and supervisory committee. The specific amendments to the Articles of Incorporation and officer appointments will be determined in the future.

Worth reading
70In focus
Scored from 1 of 5 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Governance structure

監査等委員会設置会社へ移行予定(現行の機関設計はNot disclosed)

A company structure in which an audit and supervisory committee is established within the board of directors and the directors serving on the committee are responsible for auditing.

Committee1
監査等委員会:社外委員が過半数。その他の委員会は非開示
Changes this time

2026年6月24日開催予定の定時株主総会で必要な定款変更の承認を得ることを前提に、監査等委員会設置会社へ移行する予定。定款変更および役員人事の詳細は今後決定。

Governance structure
ItemDetails
Corporate Governance Structure監査等委員会設置会社へ移行予定(現行の機関設計はNot disclosed)
Committee監査等委員会:社外委員が過半数。その他の委員会はNot disclosed
Changes this time2026年6月24日開催予定の定時株主総会で必要な定款変更の承認を得ることを前提に、監査等委員会設置会社へ移行する予定。定款変更および役員人事の詳細は今後決定。
Items this document does not state (5)
Number of directorsNumber of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholder

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

委員の過半数を社外取締役で構成する監査等委員会により経営の透明性を高めること、また、業務執行の決定権限を取締役に委任して意思決定と執行を迅速化すること。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Transition to a Company with an Audit and Supervisory Committee | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) timely disclosure | Komori